Overview Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide engineered as a dual agonist of the GIP and GLP-1 receptors - the two principal incretin receptors. The peptide backbone is derived from the native GIP sequence and includes two 2-aminoisobutyric acid (Aib) residues that confer resistance to DPP-IV degradation, together with a C20 fatty-diacid chain attached at Lys20 that promotes reversible albumin binding and a circulating half-life of roughly five days.[1][4] Native GIP and

How does GLP2-T work? What is its mechanism of action?

Mechanism of Action Dual Incretin Receptor Agonism Tirzepatide is a full agonist at both the GIP receptor and the GLP-1 receptor - class B (secretin-family) Gs-coupled GPCRs expressed on pancreatic beta-cells and alpha-cells, adipocytes, and central-nervous-system neurons. Receptor occupancy elevates intracellular cAMP and activates PKA signaling, which in the beta-cell potentiates glucose-dependent insulin secretion.[4][2] Imbalanced / Biased Agonism Pharmacology studies describe tirzepatide as

What are the research applications of GLP2-T?

Research Applications Tirzepatide is studied in preclinical and clinical research that probes dual GIP/GLP-1 receptor biology and its downstream metabolic effects. Reported research applications include: Dual-Incretin-Receptor Pharmacology - Used as a high-potency, DPP-IV-resistant co-agonist probe to characterize GIP-receptor and GLP-1-receptor coupling, cAMP/beta-arrestin balance, and receptor desensitization kinetics in recombinant cell-line and primary islet systems.[4] Glucose-Dependent Ins

How should GLP2-T be stored?

Store lyophilized at 2-8C (refrigerated), protected from light.

GLP2-T: Safety Profile & Research Summary

Q: What does the research summary say about GLP2-T?

Research Summary Foundational Studies StudyModelKey FindingsRef Coskun et al. (2018)Cell/rodent + phase 1First unimolecular dual GIP/GLP-1 receptor agonist; discovery-to-proof-of-concept characterization[1] Willard et al. (2020)Recombinant receptor assaysCharacterized tirzepatide as an imbalanced/biased dual agonist (GIP-like at GIPR; biased at GLP-1R)[4] Rosenstock et al. (2021)SURPASS-1 (Phase 3)Phase 3, placebo-controlled trial of the pharmaceutical product; see reference[6] Frias et al. (202

A partir de $69.30 · COAs de lote publicados para 3 de 4 tamanhos · Água BAC grátis + frete grátis nos EUA · Despacho no mesmo dia antes das 14h ET · APENAS PARA USO EM PESQUISA

Comprar peptídeo GLP2-T - todos os tamanhos

8 Citacoes PubMedRevisado por EspecialistasUltima Revisao: julho de 2026

Research Summary

Foundational Studies

Study	Model	Key Findings	Ref
Coskun et al. (2018)	Cell/rodent + phase 1	First unimolecular dual GIP/GLP-1 receptor agonist; discovery-to-proof-of-concept characterization	[1]
Willard et al. (2020)	Recombinant receptor assays	Characterized tirzepatide as an imbalanced/biased dual agonist (GIP-like at GIPR; biased at GLP-1R)	[4]
Rosenstock et al. (2021)	SURPASS-1 (Phase 3)	Phase 3, placebo-controlled trial of the pharmaceutical product; see reference	[6]
Frias et al. (2021)	SURPASS-2 (Phase 3)	Phase 3, active-comparator trial of the pharmaceutical product; see reference	[5]
Samms et al. (2020)	Review / preclinical	Mechanistic framework for how GIP-receptor agonism may enhance GLP-1 efficacy	[7]

Tirzepatide is the active ingredient of FDA-approved pharmaceuticals; that approval does not apply to this research-grade material. See References.

Mechanistic Themes

Dual incretin agonism - a single peptide engages both the GIP and GLP-1 receptors
Imbalanced/biased signaling - GIP-like at GIPR, biased (cAMP-favoring) at GLP-1R
Extended pharmacokinetics - Aib substitutions plus C20 fatty-diacid albumin binding support ~5-day half-life
Glucose-dependent action - insulinotropic effect is conditioned on ambient glucose

In Vitro / Preclinical Disclaimer: The research findings described above were observed in laboratory (in vitro), animal model, and clinical research studies of the pharmaceutical product. Research-grade material supplied by Pure U.S. Peptides is for laboratory research use only. No claims are made regarding human therapeutic use of this research-grade product.

Educational Use Only: This content summarises published laboratory and clinical literature for research reference only. It is not medical advice.

Editorial Research Note

“(2018)Cell/rodent + phase 1First unimolecular dual GIP/GLP-1 receptor agonist; discovery-to-proof-of-concept characterization[1] Willard et al.”

Pure U.S. Peptides Research Standards TeamInternal editorial group summarising published peptide research for an audience of qualified independent investigators.

Referencias

Perguntas de Pesquisa Relacionadas

→ What Is GLP2-T?→ GLP2-T: Mechanism of Action → GLP2-T: Research Applications → GLP2-T: Chemical Properties → Storing GLP2-T: Best Practices

Related research

GLP3-R — Safety profile Cagriniltide — Safety profile

Browse all research guides in the Peptide Research Library →

Deseja a revisao completa da pesquisa?

Comprar peptídeo GLP2-T - todos os tamanhos→

APENAS PARA USO EM PESQUISA

Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.